Penn Medicine is going all in on proton therapy, a costly treatment that is unproven for most common cancers Penn In the News Philadelphia Inquirer Penn Medicine is going all in on proton therapy, a costly treatment that is unproven for most common cancers A profile examines Penn Medicine’s commitment to the advancement of proton therapy, a new radiation cancer treatment, with remarks from James Metz and Justin E. Bekelman of the Perelman School of Medicine. For breast cancer patients, Penn researchers are comparing costly proton therapy with standard radiation Penn In the News Philadelphia Inquirer For breast cancer patients, Penn researchers are comparing costly proton therapy with standard radiation The Perelman School of Medicine’s Justin E. Bekelman is leading a $12 million study to compare the effects of proton therapy and standard radiation treatment on breast cancer. The race to supercharge cancer-fighting T cells Penn In the News Nature The race to supercharge cancer-fighting T cells Carl June and Avery Posey of the Perelman School of Medicine discuss the progression and expansion of CAR-T cell therapies. Machine learning-triggered reminders improve end-of-life care for patients with cancer Machine learning-triggered reminders improve end-of-life care for patients with cancer The rates of advanced care planning conversations quadrupled, while potentially harmful therapy at end of life decreased by 25% in large randomized study. CAR T cell therapy may eliminate tumor cells missed by surgery CAR T cell therapy may eliminate tumor cells missed by surgery The results of a study led by Penn Medicine’s Carl June greenlights preclinical trials for the application of CAR T therapy in gel form to surgical wounds following partial tumor removal to eliminate residual tumor cells. The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. (Image: Penn Medicine News) The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery The injectable diagnostic, Cytalux, binds to cancerous tissue and glows, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Advances in cancer research Interleukin-18 is a protein which in humans is encoded by the IL18 gene. “We designed an ‘armored’ CAR that secretes IL18 where we found it to have potent antitumor efficacy in our preclinical studies,” said Carl June. (Image: Penn Medicine News) Advances in cancer research Recent research shows promise in a novel CAR T therapy after cancer relapse, and a novel treatment for multiple myeloma. How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes A new study from the School of Nursing examines the association between patients’ perceived benefits and burdens of research participation and withdrawal. Another Crispr first: New treatment wipes out teen’s cancer Penn In the News The Washington Post Another Crispr first: New treatment wipes out teen’s cancer Bruce Levine of the Perelman School of Medicine says that the latest results of Crispr gene editing in a cancer patient have showcased the best possible clinical outcome thus far. Load More
For breast cancer patients, Penn researchers are comparing costly proton therapy with standard radiation Penn In the News Philadelphia Inquirer For breast cancer patients, Penn researchers are comparing costly proton therapy with standard radiation The Perelman School of Medicine’s Justin E. Bekelman is leading a $12 million study to compare the effects of proton therapy and standard radiation treatment on breast cancer. The race to supercharge cancer-fighting T cells Penn In the News Nature The race to supercharge cancer-fighting T cells Carl June and Avery Posey of the Perelman School of Medicine discuss the progression and expansion of CAR-T cell therapies. Machine learning-triggered reminders improve end-of-life care for patients with cancer Machine learning-triggered reminders improve end-of-life care for patients with cancer The rates of advanced care planning conversations quadrupled, while potentially harmful therapy at end of life decreased by 25% in large randomized study. CAR T cell therapy may eliminate tumor cells missed by surgery CAR T cell therapy may eliminate tumor cells missed by surgery The results of a study led by Penn Medicine’s Carl June greenlights preclinical trials for the application of CAR T therapy in gel form to surgical wounds following partial tumor removal to eliminate residual tumor cells. The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. (Image: Penn Medicine News) The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery The injectable diagnostic, Cytalux, binds to cancerous tissue and glows, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Advances in cancer research Interleukin-18 is a protein which in humans is encoded by the IL18 gene. “We designed an ‘armored’ CAR that secretes IL18 where we found it to have potent antitumor efficacy in our preclinical studies,” said Carl June. (Image: Penn Medicine News) Advances in cancer research Recent research shows promise in a novel CAR T therapy after cancer relapse, and a novel treatment for multiple myeloma. How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes A new study from the School of Nursing examines the association between patients’ perceived benefits and burdens of research participation and withdrawal. Another Crispr first: New treatment wipes out teen’s cancer Penn In the News The Washington Post Another Crispr first: New treatment wipes out teen’s cancer Bruce Levine of the Perelman School of Medicine says that the latest results of Crispr gene editing in a cancer patient have showcased the best possible clinical outcome thus far. Load More
The race to supercharge cancer-fighting T cells Penn In the News Nature The race to supercharge cancer-fighting T cells Carl June and Avery Posey of the Perelman School of Medicine discuss the progression and expansion of CAR-T cell therapies. Machine learning-triggered reminders improve end-of-life care for patients with cancer Machine learning-triggered reminders improve end-of-life care for patients with cancer The rates of advanced care planning conversations quadrupled, while potentially harmful therapy at end of life decreased by 25% in large randomized study. CAR T cell therapy may eliminate tumor cells missed by surgery CAR T cell therapy may eliminate tumor cells missed by surgery The results of a study led by Penn Medicine’s Carl June greenlights preclinical trials for the application of CAR T therapy in gel form to surgical wounds following partial tumor removal to eliminate residual tumor cells. The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. (Image: Penn Medicine News) The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery The injectable diagnostic, Cytalux, binds to cancerous tissue and glows, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Advances in cancer research Interleukin-18 is a protein which in humans is encoded by the IL18 gene. “We designed an ‘armored’ CAR that secretes IL18 where we found it to have potent antitumor efficacy in our preclinical studies,” said Carl June. (Image: Penn Medicine News) Advances in cancer research Recent research shows promise in a novel CAR T therapy after cancer relapse, and a novel treatment for multiple myeloma. How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes A new study from the School of Nursing examines the association between patients’ perceived benefits and burdens of research participation and withdrawal. Another Crispr first: New treatment wipes out teen’s cancer Penn In the News The Washington Post Another Crispr first: New treatment wipes out teen’s cancer Bruce Levine of the Perelman School of Medicine says that the latest results of Crispr gene editing in a cancer patient have showcased the best possible clinical outcome thus far. Load More
Machine learning-triggered reminders improve end-of-life care for patients with cancer Machine learning-triggered reminders improve end-of-life care for patients with cancer The rates of advanced care planning conversations quadrupled, while potentially harmful therapy at end of life decreased by 25% in large randomized study.
CAR T cell therapy may eliminate tumor cells missed by surgery CAR T cell therapy may eliminate tumor cells missed by surgery The results of a study led by Penn Medicine’s Carl June greenlights preclinical trials for the application of CAR T therapy in gel form to surgical wounds following partial tumor removal to eliminate residual tumor cells.
The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression. (Image: Penn Medicine News) The Jin Lab taps into a key cell for cancer research The lab, led by Chengcheng Jin, an assistant professor of cancer biology and microbiology, is investigating how the immune system co-evolves with tumors during cancer progression.
FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery FDA approves ‘glowing tumor’ imaging drug to aid lung cancer surgery The injectable diagnostic, Cytalux, binds to cancerous tissue and glows, making it easier for surgeons to remove tumors completely while sparing healthy tissue.
Advances in cancer research Interleukin-18 is a protein which in humans is encoded by the IL18 gene. “We designed an ‘armored’ CAR that secretes IL18 where we found it to have potent antitumor efficacy in our preclinical studies,” said Carl June. (Image: Penn Medicine News) Advances in cancer research Recent research shows promise in a novel CAR T therapy after cancer relapse, and a novel treatment for multiple myeloma.
How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes How the perception of risks and benefits influence cancer clinical trial withdrawal outcomes A new study from the School of Nursing examines the association between patients’ perceived benefits and burdens of research participation and withdrawal.
Another Crispr first: New treatment wipes out teen’s cancer Penn In the News The Washington Post Another Crispr first: New treatment wipes out teen’s cancer Bruce Levine of the Perelman School of Medicine says that the latest results of Crispr gene editing in a cancer patient have showcased the best possible clinical outcome thus far.